| ALTEROLA-BIOTECH-INC |
ALTEROLA-BIOTECH-INC |
62%
|
d journals. He currently divides his time between his clinical and academic activities at The Methodist Hospital and ITESM. Prior to being appointed to Cardiol’s Board of Directors, Dr. Torre-Amione … |
| ASHBURY-BIOLOGICALS-INC |
ASHBURY-BIOLOGICALS-INC |
62%
|
d journals. He currently divides his time between his clinical and academic activities at The Methodist Hospital and ITESM. Prior to being appointed to Cardiol’s Board of Directors, Dr. Torre-Amione … |
| CARDIOL-THERAPEUTICS-USA-INC |
CARDIOL-THERAPEUTICS-USA-INC |
62%
|
nabinoid-based treatments. The parties with which the Corporation does business may perceive that they are exposed to reputational risk as a result of the Corporation’s cannabinoid-related activities… |
| COMMON-SHARES-THE-CORPORATION |
COMMON-SHARES-THE-CORPORATION |
62%
|
nabinoid-based treatments. The parties with which the Corporation does business may perceive that they are exposed to reputational risk as a result of the Corporation’s cannabinoid-related activities… |
| COMPUTERSHARE-TRUST-COMPANY |
COMPUTERSHARE-TRUST-COMPANY |
62%
|
bursement for our product candidates; ● the level of pricing and reimbursement for our product candidates, if approved; ● our dependence on contract manufacturers; ● unsuccessful collaborations with … |
| CORPORATION-CARDIOL-THERAPEUTICS-USA-INC |
CORPORATION-CARDIOL-THERAPEUTICS-USA-INC |
62%
|
bursement for our product candidates; ● the level of pricing and reimbursement for our product candidates, if approved; ● our dependence on contract manufacturers; ● unsuccessful collaborations with … |
| CORPORATION-THE-CORPORATION |
CORPORATION-THE-CORPORATION |
62%
|
a manufacturer and distributor of products designed to be ingested by humans, the Corporation faces an inherent risk of exposure to product liability claims, regulatory action, and litigation if its … |
| DALTON-CHEMICAL-LABORATORIES-INC |
DALTON-CHEMICAL-LABORATORIES-INC |
62%
|
bursement for our product candidates; ● the level of pricing and reimbursement for our product candidates, if approved; ● our dependence on contract manufacturers; ● unsuccessful collaborations with … |
| INCORPORATION-THE-CORPORATION |
INCORPORATION-THE-CORPORATION |
62%
|
nabinoid-based treatments. The parties with which the Corporation does business may perceive that they are exposed to reputational risk as a result of the Corporation’s cannabinoid-related activities… |
| MEROS-POLYMERS-INC |
MEROS-POLYMERS-INC |
62%
|
bursement for our product candidates; ● the level of pricing and reimbursement for our product candidates, if approved; ● our dependence on contract manufacturers; ● unsuccessful collaborations with … |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
bursement for our product candidates; ● the level of pricing and reimbursement for our product candidates, if approved; ● our dependence on contract manufacturers; ● unsuccessful collaborations with … |
| PURISYS-LLC |
PURISYS-LLC |
62%
|
bursement for our product candidates; ● the level of pricing and reimbursement for our product candidates, if approved; ● our dependence on contract manufacturers; ● unsuccessful collaborations with … |
| SARBANES-OXLEY-ACT-THE-CORPORATION |
SARBANES-OXLEY-ACT-THE-CORPORATION |
62%
|
nabinoid-based treatments. The parties with which the Corporation does business may perceive that they are exposed to reputational risk as a result of the Corporation’s cannabinoid-related activities… |
| U-S-EXCHANGE-ACT-THE-CORPORATION |
U-S-EXCHANGE-ACT-THE-CORPORATION |
62%
|
nabinoid-based treatments. The parties with which the Corporation does business may perceive that they are exposed to reputational risk as a result of the Corporation’s cannabinoid-related activities… |
